These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22714546)

  • 61. Maximum Likelihood Estimation in a Semicontinuous Survival Model with Covariates Subject to Detection Limits.
    Bernhardt PW
    Int J Biostat; 2018 Oct; 14(2):. PubMed ID: 30379638
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Estimating Outcome-Exposure Associations when Exposure Biomarker Detection Limits vary Across Batches.
    Boss J; Mukherjee B; Ferguson KK; Aker A; Alshawabkeh AN; Cordero JF; Meeker JD; Kim S
    Epidemiology; 2019 Sep; 30(5):746-755. PubMed ID: 31299670
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A semiparametric method for comparing the discriminatory ability of biomarkers subject to limit of detection.
    Yin L; Diao G; Liu A
    Stat Med; 2017 Nov; 36(26):4141-4152. PubMed ID: 28744876
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bayesian inference for a nonlinear mixed-effects Tobit model with multivariate skew-t distributions: application to AIDS studies.
    Dagne G; Huang Y
    Int J Biostat; 2012 Sep; 8(1):. PubMed ID: 22992288
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Estimating correlation with multiply censored data arising from the adjustment of singly censored data.
    Newton E; Rudel R
    Environ Sci Technol; 2007 Jan; 41(1):221-8. PubMed ID: 17265951
    [TBL] [Abstract][Full Text] [Related]  

  • 67. ROC curve inference for best linear combination of two biomarkers subject to limits of detection.
    Perkins NJ; Schisterman EF; Vexler A
    Biom J; 2011 May; 53(3):464-76. PubMed ID: 22223252
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sample size and statistical power assessing the effect of interventions in the context of mixture distributions with detection limits.
    Chu H; Nie L; Cole SR
    Stat Med; 2006 Aug; 25(15):2647-57. PubMed ID: 16456897
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Between-group comparison of area under the curve in clinical trials with censored follow-up: Application to HIV therapeutic vaccines.
    Alexandre M; Prague M; Thiébaut R
    Stat Methods Med Res; 2021 Sep; 30(9):2130-2147. PubMed ID: 34218746
    [TBL] [Abstract][Full Text] [Related]  

  • 70. GEE with Gaussian estimation of the correlations when data are incomplete.
    Lipsitz SR; Molenberghs G; Fitzmaurice GM; Ibrahim J
    Biometrics; 2000 Jun; 56(2):528-36. PubMed ID: 10877313
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Estimation in generalized linear models under censored covariates with an application to MIREC data.
    Lee WC; Sinha SK; Arbuckle TE; Fisher M
    Stat Med; 2018 Dec; 37(29):4539-4556. PubMed ID: 30168157
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sufficient dimension reduction for censored predictors.
    Tomassi D; Forzani L; Bura E; Pfeiffer R
    Biometrics; 2017 Mar; 73(1):220-231. PubMed ID: 27506481
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Analysis of lognormally distributed exposure data with repeated measures and values below the limit of detection using SAS.
    Jin Y; Hein MJ; Deddens JA; Hines CJ
    Ann Occup Hyg; 2011 Jan; 55(1):97-112. PubMed ID: 21177260
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Statistical Inference of the Generalized Inverted Exponential Distribution under Joint Progressively Type-II Censoring.
    Chen Q; Gui W
    Entropy (Basel); 2022 Apr; 24(5):. PubMed ID: 35626461
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Measuring association among censored antibody titer data.
    Tran TMP; Abrams S; Aerts M; Maertens K; Hens N
    Stat Med; 2021 Jul; 40(16):3740-3761. PubMed ID: 33942345
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lasso regularization for left-censored Gaussian outcome and high-dimensional predictors.
    Soret P; Avalos M; Wittkop L; Commenges D; Thiébaut R
    BMC Med Res Methodol; 2018 Dec; 18(1):159. PubMed ID: 30514234
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Joint modeling of longitudinal data and informative dropout time in the presence of multiple changepoints.
    Ghosh P; Ghosh K; Tiwari RC
    Stat Med; 2011 Mar; 30(6):611-26. PubMed ID: 21337357
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Assay validation for left-censored data.
    Barnhart HX; Song J; Lyles RH
    Stat Med; 2005 Nov; 24(21):3347-60. PubMed ID: 15977288
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Linear censored regression models with skew scale mixtures of normal distributions.
    Guzmán DCF; Ferreira CS; Zeller CB
    J Appl Stat; 2021; 48(16):3060-3085. PubMed ID: 35707255
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Markov chain Monte Carlo EM algorithm for analyzing interval-censored data under the Cox proportional hazards model.
    Goggins WB; Finkelstein DM; Schoenfeld DA; Zaslavsky AM
    Biometrics; 1998 Dec; 54(4):1498-507. PubMed ID: 9883548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.